Literature DB >> 16160150

Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.

Marc F Le Mire1, Darren S Miller, Wendy K Foster, Christopher J Burrell, Allison R Jilbert.   

Abstract

Residual hepatitis B virus (HBV) DNA can be detected in serum and liver after apparent recovery from transient infection. However, it is not known if this residual HBV DNA represents ongoing viral replication and antigen expression. In the current study, ducks inoculated with duck hepatitis B virus (DHBV) were monitored for residual DHBV DNA following recovery from transient infection until 9 months postinoculation (p.i.). Resolution of DHBV infection occurred in 13 out of 15 ducks by 1-month p.i., defined as clearance of DHBV surface antigen-positive hepatocytes from the liver and development of anti-DHBV surface antibodies. At 9 months p.i., residual DHBV DNA was detected using nested PCR in 10/11 liver, 7/11 spleen, 2/11 kidney, 1/11 heart, and 1/11 adrenal samples. Residual DHBV DNA was not detected in serum or peripheral blood mononuclear cells. Within the liver, levels of residual DHBV DNA were 0.0024 to 0.016 copies per cell, 40 to 80% of which were identified as covalently closed circular viral DNA by quantitative PCR assay. This result, which was confirmed by Southern blot hybridization, is consistent with suppressed viral replication or inactive infection. Samples of liver and spleen cells from recovered animals did not transmit DHBV infection when inoculated into 1- to 2-day-old ducklings, and immunosuppressive treatment of ducks with cyclosporine and dexamethasone for 4 weeks did not alter levels of residual DHBV DNA in the liver. These findings further characterize a second form of hepadnavirus persistence in a suppressed or inactive state, quite distinct from the classical chronic carrier state.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16160150      PMCID: PMC1211519          DOI: 10.1128/JVI.79.19.12242-12252.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Integration of hepadnavirus DNA in infected liver: evidence for a linear precursor.

Authors:  W Yang; J Summers
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

2.  Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen.

Authors:  H Marusawa; S Uemoto; M Hijikata; Y Ueda; K Tanaka; K Shimotohno; T Chiba
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

3.  Studying host immune responses against duck hepatitis B virus infection.

Authors:  Darren S Miller; Edward M Bertram; Catherine A Scougall; Ieva Kotlarski; Allison R Jilbert
Journal:  Methods Mol Med       Date:  2004

4.  [Concept of species in the light of recent biochemical data & the L cycle].

Authors:  R VENDRELY
Journal:  Ann Inst Pasteur (Paris)       Date:  1958-02

5.  Sequence comparison of an Australian duck hepatitis B virus strain with other avian hepadnaviruses.

Authors:  Miriam Triyatni; Peter L Ey; Thien Tran; Marc Le Mire; Ming Qiao; Christopher J Burrell; Allison R Jilbert
Journal:  J Gen Virol       Date:  2001-02       Impact factor: 3.891

6.  The effects of cyclosporin A on the chicken immune system.

Authors:  J S Nowak; O Kai; R Peck; R M Franklin
Journal:  Eur J Immunol       Date:  1982-10       Impact factor: 5.532

7.  Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.

Authors:  Wendy K Foster; Darren S Miller; Patricia L Marion; Richard J Colonno; Ieva Kotlarski; Allison R Jilbert
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

8.  Hepatitis B virus DNA forms in nuclear and cytoplasmic fractions of infected human liver.

Authors:  R H Miller; W S Robinson
Journal:  Virology       Date:  1984-09       Impact factor: 3.616

9.  Effect of cyclosporin A on spontaneous autoimmune thyroiditis of Obese strain (OS) chickens.

Authors:  G Wick; P U Müller; S Schwarz
Journal:  Eur J Immunol       Date:  1982-10       Impact factor: 5.532

10.  A duck hepatitis B virus strain with a knockout mutation in the putative X ORF shows similar infectivity and in vivo growth characteristics to wild-type virus.

Authors:  P Meier; C A Scougall; H Will; C J Burrell; A R Jilbert
Journal:  Virology       Date:  2003-12-20       Impact factor: 3.616

View more
  7 in total

Review 1.  Hepatitis B virus replication.

Authors:  Juergen Beck; Michael Nassal
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

2.  Activity of nucleic acid polymers in rodent models of HBV infection.

Authors:  Katrin Schöneweis; Neil Motter; Pia L Roppert; Mengji Lu; Baoju Wang; Ingo Roehl; Dieter Glebe; Dongliang Yang; John D Morrey; Michael Roggendorf; Andrew Vaillant
Journal:  Antiviral Res       Date:  2017-11-08       Impact factor: 5.970

Review 3.  Molecular mechanisms underlying occult hepatitis B virus infection.

Authors:  Jasmine Samal; Manish Kandpal; Perumal Vivekanandan
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

4.  Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA.

Authors:  Kouichi Kitamura; Zhe Wang; Sajeda Chowdhury; Miyuki Simadu; Miki Koura; Masamichi Muramatsu
Journal:  PLoS Pathog       Date:  2013-05-16       Impact factor: 6.823

Review 5.  Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks.

Authors:  Patrick T F Kennedy; Samuel Litwin; Grace E Dolman; Antonio Bertoletti; William S Mason
Journal:  Viruses       Date:  2017-04-29       Impact factor: 5.048

6.  Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks.

Authors:  Jonathan Quinet; Catherine Jamard; Madeleine Burtin; Matthieu Lemasson; Sylviane Guerret; Camille Sureau; Andrew Vaillant; Lucyna Cova
Journal:  Hepatology       Date:  2018-02-23       Impact factor: 17.425

7.  Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection.

Authors:  Faseeha Noordeen; Catherine A Scougall; Arend Grosse; Qiao Qiao; Behzad B Ajilian; Georget Reaiche-Miller; John Finnie; Melanie Werner; Ruth Broering; Joerg F Schlaak; Andrew Vaillant; Allison R Jilbert
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.